for the CONSORT-CHM Formulas 2017 Group* Chinese herbal medicine (CHM) formulas are the major components of traditional Chinese medicine (TCM) interventions. The general reporting quality of randomized controlled trials (RCTs) of CHM formulas is disappointing, although CONSORT (Consolidated Standards of Reporting Trials) Statement extensions for herbal medicinal interventions and acupuncture interventions are available. A group of TCM clinical experts, methodologists, epidemiologists, and editors has developed this CONSORT Extension for CHM Formulas (CONSORT-CHM Formulas 2017) through a comprehensive process, including publication of the draft version, solicitation of comments, revision, and finalization.
T
raditional Chinese medicine (TCM), one of the oldest medical systems in the world, is based on its own unique principles and comprehensive theory. Today, it plays an indispensable role in the Chinese health care system, and its impact worldwide is increasing (1) . Since the first randomized controlled trial (RCT) of a Chinese herbal medicine (CHM) formula was published in 1982 (2) , tens of thousands of clinical reports have been published (3) . However, the quality of reporting is not optimal (4 -6). Inadequate reporting not only compromises the values of the CHM but also may affect reviewers' and readers' judgments about the efficacy and safety of TCM in general, inviting skepticism and criticism (6) . As a result, clinical practice and patient care suffer.
The CONSORT (Consolidated Standards of Reporting Trials) Statement and its extensions have substantially improved the reporting quality of RCTs (7) . CONSORT extensions for herbal medicinal interventions (8) and acupuncture interventions (9) have been developed, but neither can be used for reporting clinical trials of CHM formulas, which are the most common interventions in TCM practice. These CONSORT extensions do not adequately take into account the unique characteristics of TCM-theory, principles, formulas, and Chinese medicinal substances (Boxes 1 to 4). Therefore, a new extension has been developed to guide the reporting of trials using CHM formulas.
METHODS FOR THE DEVELOPMENT OF CONSORT-CHM FORMULAS 2017
The development of CONSORT-CHM Formulas (formerly known as CONSORT for TCM) has been a comprehensive process. The first draft of CONSORT-CHM Formulas, including a 22-item checklist and a flow diagram, was published in Chinese (16) and English (17) in 2007 for open solicitation of comments. Afterward, the draft was disseminated in workshops and academic conferences by executive members of the working group to attract further discussion. Articles on the significance of the CHM formula extension (18) , study design rationale (19) , CHM formula composition (20) , outcome measures (21) , adverse effects (22) , and further development (23) were published in Chinese or English.
On the basis of the comments and suggestions received, as well as the 2010 version of CONSORT Statement (24), executive members of the working group discussed and revised this extension in Chengdu, China, in late 2012. A consensus meeting, including executive members of working groups, 12 TCM clinical trial experts from China, and 2 herbal medicine experts from Korea, was held in Beijing in June 2013. After the meeting, a further revision was made by executive members and circulated to the working group members. The executive working group finalized the recommendation at the end of 2016.
item, keywords (item 1c). It elaborates on 7 of 25 CONSORT checklist items, namely title and abstract (items 1a and 1b), background and objectives (items 2a and 2b), participants (item 4a), interventions (item 5), outcomes (item 6a), generalizability (item 21), and interpretation (item 22) , and it revises the explanation of harms specific to CHM formulas (item 19) . The items from the Template for Intervention Description and Replication (TIDieR) are also combined in this extension (25) .
The checklist is presented in the [26, 27] Every scientific paper should have a selfexplanatory title, a comprehensive abstract, and appropriate keywords (tags readers use to retrieve relevant literature from bibliographic databases). Identifying RCTs of CHM formulas is particularly challenging (3). In general, authors give only the name of the CHM formula and the target disease in the keywords. Different from conventional medicine, the name of a CHM formula can be an English translation, Chinese Pinyin, or an acronym. Reader may have difficulties in determining whether the name of the intervention is a Chinese herbal formula. When authors use the general term "Chinese herbal medicine," they can be referring to a Chinese medicinal component, single herb, or compound formula. This vagueness, inconsistency, and incompleteness impede access to and dissemination of information from clinical trials of CHM formulas and discourage secondary studies. To ensure that a CHM Box 1. Fundamental principles of traditional Chinese medicine theory.
Traditional Chinese medicine (TCM) is a unique and systematic medical system deeply influenced by ancient Chinese philosophy. It believes that the human body is an organic whole, which is closely tied with the universe. Therefore, the activities of nature can affect the human body directly or indirectly. Distinctive theories of Qi, Yin-Yang, and the Five Elements commonly used to understand and explain natural phenomena are fundamental to TCM theory (10).
Qi, also translated as "vital energy," is the basic substance that constitutes the universe. This basic understanding gives rise to the key medical concept in TCM. Yin and Yang are 2 relative opposite manifestations of Qi, namely Yang-Qi and Yin-Qi, and they are opposite and restraint, mutual dependent and supportive, equilibrium and waning, and mutual transformable. The theory of Yin and Yang forms the TCM theoretical structure. The theory of the Five Elements holds that the universe comprises Wood, Fire, Earth, Metal, and Water, and the phenomena of universe come from the movements of and changes in the Five Elements. The interpromoting and interrestraining of the Five Elements are complementary. Promotion and restraint among the Five Elements bear each other, and only in this way can relative harmony and coordination of the internal organs be maintained. These fundamental ideas are especially important for understanding the structure of the body, physiology, and pathology and for guiding clinical diagnosis and treatment in TCM (10). study is appropriately indexed and easily identified, a new CONSORT subitem keywords (item 1c) is recommended. Apart from the name of the intervention, "Chinese herbal medicine formula" and "randomized controlled trial" are recommended keywords. The background and underlying rationale of the study design are important to provide in the introduction of a scientific paper. For any study of CHM formulas, whether the rationale is based on biomedical science findings, TCM theory, or both should be elucidated. This section should preferably include a reference to a pilot study or literature review. Moreover, any evidence of the benefits and harms of the CHM formula studied and its active ingredients should also be reported.
Background and Objectives

Item 2a
Standard
The objectives or hypotheses are the questions that the trial is designed to answer. Whether the CHM formula targets a Western medicine-defined disease, a Pattern, or a Western medicine-defined disease with a specific Pattern should be clarified. Readers can then easily understand which conditions are targeted in the trial, and the results will be more easily applied in clinical practice. Chinese herbal interventions are always in the form of formulas with multiple medical substances. The reproducibility of a CHM formula highly depends on whether the substances and related authentication, modification, processing, and production are reported in enough detail. Otherwise, the whole study cannot be replicated by other researchers (33) . Therefore, item 5 (interventions) is revised to include the reporting recommendations for common types of CHM formulas (fixed, individualized, and patent proprietary) and their controls (placebo and active). Also, the TIDieR checklist items were embedded (25) . Readers can follow the reporting items for each type of CHM formulas one by one.
Participants
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In addition, quality control methods used for the substances and preparation of the formula should be reported and should detail any references used, such as pharmacopoeias from different countries and regions. The Chinese pharmacopoeia is an official monograph citing the preparation details and quality control of 2165 crude Chinese medicinal substances, patent proprietary drugs, extracts, and others (34) . The Japanese pharmacopeia records the methods of preparations and quality control of 148 formulations (mainly herbal extracts) (35) . These are important references that authors can cite in reporting the details of CHM formulas used in RCTs.
The choice of control group affects the conclusions that can be drawn from the study, such as whether the outcomes are caused by the treatment effects, the natural progression of the disease, observer or patient expectations, or any other potential influences (36) . Among these, placebo design of CHM formulas has been the topic of lively discussion for years. Designing a placebo similar to the formula product with identical color, smell, taste, and texture yet without active properties is not only a science but also an art (36) . Transparently reporting the name and amount of each ingredient; processing method; quality control and safety assessment; administration route, regimen, and dosage; and success of masking (if applicable) are essential for readers to assess the validity of study results and to be able to duplicate the study protocol.
We emphasize that the information about quality, safety, and efficacy of CHM formulas should be reported in detail. A complete description helps readers to easily understand the results of a trial. Any novel application of a fixed or patent proprietary CHM formula for conditions different from those traditionally treated, should be well-illustrated by providing the underlying rationale and supporting evidence. Further, we understand that some items in the checklist, especially quality control methods, are not easily achieved at the current stage. By making the reporting recommendation more practical, we allow a compromise proposal with "if any," but it does not mean that these items are not crucial. From the beginning of trial preparation, efforts should be made to produce the highestquality study in every aspect, including the preparation of CHM interventions. Following these guidelines will make the trial transparent, secure the safety of participants, and thereby increase the scientific value of the trial results.
Outcomes
Item 6a
Standard CONSORT item: Completely defined, prespecified primary and secondary outcome measures, including how and when they were assessed
CHM Formulas extension: Illustration of outcome measures with Pattern in detail
Valid and reliable outcome measures are prerequisites to justify any conclusion regarding the efficacy and safety of an intervention. Commonly used indices for outcome measures in an RCT of a CHM formula can be categorized into Western medicine-specific outcomes and TCM-specific outcomes (21) . The former is often measured using objective biomedical indices, such as blood tests, blood pressure measurements, and radiographs. The latter is more likely to include symptoms and signs assessed by TCM diagnostic methods. Outcome measures and symptoms and signs, as well as Pattern, can be measured in terms of occurrence (for example, presence or absence of an individual symptom or sign), by a rating scale (for example, 7-point ordinal scale) (37) or a validated Pattern assessment questionnaire (38) . In addition, how and by whom the outcomes with Pattern are assessed should be reported. All methods used to enhance the quality of measurement should be reported. Supporting references, underlying rationales, and details of assessment procedures must be clearly described.
Harms
Item 19
Standard CONSORT item: All important harms or unintended effects in each group (for specific guidance, see CONSORT for harms [28] )
CHM Formulas extension: (There is no extension for this item)
It is widely and mistakenly assumed that Chinese medicinal substances originating from natural sources are harmless. Therefore, harms are less emphasized in RCTs of CHM formulas (16) . In general, adverse effects derive from unpredictable adverse events, improper use, contamination, misidentification, and drug-herb interactions (23) . For CONSORT-CHM Formulas, any harms or suspected harms of a formula should be reported and explained in terms of TCM theory, biomedical science, or both. Second, outcome measures specific to safety assessment should be addressed. Third, the rationale for selection and the specific assessment methods should be defined with supporting references. Fourth, the details of all adverse events (such as time of occurrence, frequency, severity, or number of patients who withdraw or reduce their doses) should be reported. If no adverse events are reported, the author should state so ("no adverse events were reported"). Finally, in the event of any adverse effects, interpretation about the potential underlying cause is recommended.
Generalizability
Item 21
Standard CONSORT item: Generalizability (external validity, applicability) of the trial findings
CHM Formulas extension: Discussion of how the formula works on different TCM Patterns or diseases
Each CHM formula is determined on the basis of Pattern differentiation. The same method of treatment can be applied to patients with different diseases but with the same Pattern. On the other hand, different CHM formulas can be applied to patients with the same disease but with different Patterns. Therefore, the applicability of trial findings to different Patterns of the same disease or the same Pattern manifested as different diseases can further be discussed.
Interpretation
Item 22
Standard CONSORT item: Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence CHM Formulas extension: Interpretation with TCM theory
Pattern is the core of TCM theory and the effectiveness of a formula depends on the accuracy of Pattern differentiation. Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence in terms of Pattern is crucial. Most important, because the formula is designed on the basis of the Pattern, its application should follow the Pattern differentiation.
DISCUSSION
Several CONSORT extensions have been developed, covering aspects of design, data, and intervention (www.consort-statement.org/extensions). CONSORT-CHM Formulas is developed to expand CONSORT by applying the principles of transparency, consistency, and full disclosure in the use of CHM formulas in RCTs.
The checklist of CONSORT-CHM Formulas was completed through extensive consultations with and solicitation of comments from epidemiologists, journal editors, clinical research methodologists, and TCM clinicians for over a decade. Concerns about the checklist were raised from others in the field. In December 2016, searches of the China Academic Journals Full-text Database and PubMed with "CONSORT for TCM" or "Consolidated Standards of Reporting Trials for Traditional Chinese Medicine" yielded 141 articles related to the CONSORT-CHM Formulas 2017 RESEARCH AND REPORTING METHODS draft version of CONSORT-CHM Formulas. Of these, 24 systematic reviews had used the checklist to appraise the quality of included studies, and 70 articles had cited or supported adherence to the draft when reporting RCTs of CHM formulas.
We understand that all requirements set in the extension may not be easy to meet at this stage. We emphasize that all items are critically related to the quality of RCTs with CHM formulas. Trial quality relies on design, implementation, and reporting. Therefore, researchers are expected to do their best, starting from the study design, preparation, and implementation, not only the final reporting stage.
The value of a recommendation ultimately depends on its use. The CONSORT Statement has achieved great success in encouraging implementation of research-based recommendations, ensuring changes in practice and improving the general quality of RCTs. For better dissemination of CONSORT-CHM Formulas, specific strategies are indispensable. We hope to introduce the extension to all TCM practitioners, researchers, peer reviewers, and journal editors through medical programs, workshops, and conferences. At the same time, the working group welcomes and collects comments and feedback from those in research or clinical practice in order to revise CONSORT-CHM Formulas and keep it relevant. Further, journals can play an important role if they endorse the use of CONSORT-CHM Formulas. Journals wanting to do so can use the following language in their instructions to authors: "[journal name] requires a completed CONSORT-CHM Formulas checklist as a condition of submission when reporting the results of clinical trial of CHM formula(s). Templates can be found at the CONSORT Web site (www.consort-statement.org/consort -statement/). You should ensure that your article, at a minimum, reports content addressed by each item of the checklist." Funding agencies can require the final report of a clinical trial to follow the recommendations of CONSORT-CHM Formulas. Finally, special grants or awards can be created for high-quality RCTs of CHM formulas adhering to the extension as well.
CONSORT-CHM Formulas 2017 expands the original CONSORT 2010 by applying its principles to the design, execution, and reporting of RCTs of CHM formulas. We hope that these recommendations will promote better reporting and influence design methods of RCTs testing CHM formulas. CONSORT-CHM Formulas 2017 will be periodically reappraised and further modified to ensure that it always serves investigators doing clinical research of CHM formulas. 
